Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds m...
Piper Sandler analyst Edward Tenthoff reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the pric...
Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target fro...
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales gui...
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...
Alnylam Pharmaceuticals (NASDAQ:ALNY) raises FY2025 sales outlook from $3.300 billion-$3.550 billion to $3.600 billion-$3.800 b...
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly earnings of $2.90 per share which beat the analyst consensus estimate ...
